M-1095
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- M-1095
- alx 0761
- ALX-0761
- alx0761
- ALX0761
- m 1095
- M-1095
- m1095
- M1095
- M1095 (Sonelokimab)
- m1095 sonelokimab
- sonelokimab
- Sonelokimab
- Sonelokimab (M1095)
- ChEMBL ID
- CHEMBL4298023
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- sonelokimab
- Type
- Antibody
- Mechanism
- Interleukin 17A inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-17A
- Protein identifier
- Q16552
- Mechanism
- Interleukin-17F inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-17F
- Protein identifier
- Q96PD4
- Mechanism
- Interleukin 17A inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-17A
- Mechanism
- Interleukin-17F inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-17F
- Condition
- Psoriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Arthritis, Psoriatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003778
- Subject identifier
- D015535
- Condition
- Hidradenitis Suppurativa
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000710
- Subject identifier
- D017497
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003778
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011849
- Highest recorded phase
- 3
- NCT03384745
- NCT05322473
- NCT06411379
- NCT06411899
- NCT05640245
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (11)
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
- Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
In development for (3)
- Hidradenitis suppurativa Phase 3
- Psoriasis Phase 2
- Psoriatic arthritis Phase 2